RGCC Tested Natural Substances and Suppliers

Published April 13th, 2025 by Lisbeth Roy

1. Agaricus Blazei Murill Power Full Health Foods Corp. 215-1 Hiraoka Shinanomachi Kamiminochigun Nagano-ken, 389- 1315 Japan Phone:  81(0)26-255-5581 Fax: 81(0)26-255-6733 Agaricus blazei Murill (subrufescens) is an edible, medicinal mushroom with characteristic, somewhat sweet taste and the fragrance of almonds, that has traditionally been used ag

PrecisionPath™ Protocol Design

Published March 29th, 2025 by Lisbeth Roy

Using Onconomics Plus Testing Results to Create an Adjunctive Functional Oncology Supportive Care Plan Introduction to Onconomics Plus Testing Onconomics Plus testing provides a detailed analysis of your unique cancer biology by evaluating the tumor's genetic and molecular profile, including the sensitivity and resistance of your cancer cells to var

Simplified RGCC Plan of Care EXAMPLE

Published March 29th, 2025 by Lisbeth Roy

Welcome to the PrecisionPath™ Program! At Doctors Studio, we are dedicated to guiding you through your journey to optimal health with compassion, precision, and cutting-edge science. The PrecisionPath™ is a functional oncology root-cause-focused program featuring the Q Restrain (Supportive Oligonucleotide Therapy), a highly personalized plan tailore

RGCC Tests Comparison Chart

Published April 9th, 2025 by Lisbeth Roy

  OncoTrace OncoTrail OncoCount Onconomics Plus Onconomics Onconomics Extracts+ Onconomics Extracts Purpose BaselineMonitoring              Cancer Type Hem + Solid             Stage All All All All All All All CTC Count ✓ ✓ ✓ ✓ ✓ ✓ ✓ Phenotype Markers ✓ ✓ Limited         Stemness Markers ✓ ✓           Genetic Expressions       ✓ ✓ ✓   Resistance Mar

PrecisionPath™ Functional Oncology

Published March 29th, 2025 by Lisbeth Roy

PrecisionPath™, An Adjunctive Functional Oncology Methodology Take Control of Your Cancer Journey with an Adjunctive Functional Oncology Method By Dr. Lisbeth Roy, DO, and Jennifer Wright, ANP, Director of Clinical Affairs at Doctors Studio A cancer diagnosis can be overwhelming, but at Doctors Studio, we believe it’s also a call to action—a chance

PROSTATE CANCER DIAGNOSIS Next Steps

Published March 29th, 2025 by Lisbeth Roy

CANCER DIAGNOSIS…. Now what? Introduction Thank you for entrusting Doctors Studio with your prostate health concerns. We have conducted the OncoTrace and Onconomics Plus test, which has confirmed a cancer diagnosis.  The cancer may be very early and therefore hard to detect by traditional diagnostics. While more traditional providers do not always r

Clinical Pearls for RGCC

Published March 27th, 2025 by Lisbeth Roy

ONCO-D-CLARE: False positives can be caused by peptides, HGH, GLP-1.  If the Onco-D-Clare is positive and the Oncotrace is negative, this scenario CAN BE REVERSED.  What are PMBCs? PMBCs, or Peripheral Mononuclear Blood Cells, are blood cells that include lymphocytes (T cells, B cells, and natural killer cells) and monocytes. These cells have a roun

Melatonin and cancer benefits

Published April 7th, 2025 by Lisbeth Roy

Abstract Background. Melatonin (MLT) is known to possess potent antioxidant, antiproliferative, immune-modulating, and hormone- modulating properties. Clinical evidence suggests that MLT may have a possible role in the treatment of cancer.The authors systematically reviewed the effects of MLT in conjunction with chemotherapy, radiotherapy, supportiv

PrecisionPath Cancer testing and monitoring management

Published March 29th, 2025 by Lisbeth Roy

PrecisionPath™ Screening and Supportive Care Journey Below is the structured sequence of interactions, including consent, education, and consultations for the client’s journey. Each step includes a brief description and a scripted narrative. Step 1: Assessment (Pre-Testing) Objective: Educate the client on the value of RGCC testing, discuss their co

SOT Therapy - Patient Guide

Published April 10th, 2025 by Lisbeth Roy

What is the SOT THERAPY?  Supportive Oligonucleotide Therapy (SOT) is a process that enables the RGCC lab to identify the specific gene sequences of different targets such as cancer, Lyme, and various viruses and design a specific oligonucleotide therapy. The SOT is uniquely tailored to each patient’s needs. It is a small oligonucleotide which is co

VISION Creating a Tech-Enabled System

Published March 29th, 2025 by Lisbeth Roy

THE DOCTORS STUDIO ROADMAP TO FULL POTENTIAL Next Steps Platform Determination: I identify specific necessary tools or platforms. Workflow Customization: Refine each workflow based on real-time team and client input. Technology Testing: Pilot each phase with selected clients to ensure smooth integration. Documentation: Develop SOPs for each workflow

FAQ for the clinic – RGCC & Q-RE Therapy

Published March 28th, 2025 by Lisbeth Roy

What is Q-RE? Q-RE (Supportive Oligonucleotide Therapy) targets the genetic instructions cancer cells use to multiply. It blocks or disrupts these instructions, making the cancer cells unable to grow or function properly. Over time, this can lead to cancer cells dying off naturally because they are no longer able to survive. How does Q-RE therapy wo

The melatonin immunomodulatory actions in radiotherapy

Published April 6th, 2025 by Lisbeth Roy

Abstract Radiotherapy has a key role in cancer treatment in more than half of patients with cancer. The management of severe side effects of this treatment modality is a limiting factor to appropriate treatment. Immune system responses play a pivotal role in many of the early and late side effects of radiation. Moreover, immune cells have a signific

ALL SUBSTANCES INFORMATION SHEET FOR RGCC PROTOCOLS

Published March 29th, 2025 by Lisbeth Roy

NATURAL SUBSTANCES INFORMATION CLASS 1 CYTOTOXIC AGENTS A cytotoxic agent is a substance that kills or damages cells, often by disrupting their division or vital functions. —----------------------------------------------------------------------------------------------------------- AGARICUS BLAZEI MURILL (Super Royal Agaricus/Emerson) BENEFITS: Enhan

Rosemary for Cancer

Published April 7th, 2025 by Lisbeth Roy

Anti-proliferative and antioxidant properties of rosemary Rosmarinus officinalis Abstract. Constituents in rosemary have shown a variety of pharmacological activities for cancer chemoprevention and therapy in in vitro and in vivo models. In order to further explore the chemopreventive properties of crude extracts of rosemary (Rosmarinus officinalis

RGCC Accreditations - July 2024

Published March 29th, 2025 by Lisbeth Roy

RGCC International - Driven by Science, Experience, Vision RGCC International is a specialized medical genetics laboratory established in 2004 by genetics pioneer Dr. Ioannis Papasotiriou, MD, PhD, SCym. His commitment to personalized cancer care and unwavering belief in the power of a patient’s genes has fueled Dr. Papasotiriou’s vision to create p

Therapies Algorythm-Flowchart 1.25.22

Published April 5th, 2025 by Lisbeth Roy

Doctors Studio PrecisionPath

Published March 29th, 2025 by Lisbeth Roy

Doctors Studio…. Doctors Studio is a premier functional oncology, functional urology,  and regenerative medicine practice dedicated to helping men achieve vibrant health and peak performance. With a focus on comprehensive, cutting-edge care, we specialize in addressing men’s most pressing health concerns, including prostate health, prostate cancer,

TREATMENT (RGCC) Cancer SOT Program

Published April 6th, 2025 by Lisbeth Roy

Why Screen for Prostate Cancer with EpiSwitch

Published March 29th, 2025 by Lisbeth Roy

Why You Should Consider Cancer Screening with EpiSwitch Cancer can begin quietly, long before any symptoms appear. Early detection often means more treatment options, better outcomes, and greater peace of mind. EpiSwitch is an innovative, blood-based screening test designed to detect specific epigenetic changes—tiny modifications to how our genes ar

TEMPLATE RGCC Plan of Care

Published March 29th, 2025 by Lisbeth Roy

VIDEO:  https://share.zight.com/6quAOZ This is a gentle reminder that Doctors Studio and its employees are not Oncologists and offer complementary cancer care only. The information presented below as part of this protocol is an assessment, interpretation, and recommendations based on the test results obtained from the Research Genetic Cancer Center

Therapy Descriptions

Published April 11th, 2025 by Lisbeth Roy

RGCC International Test Descriptions RGCC Screening test: Onco-D-clare: Onco-D-clare is a cancer screening test based on the interaction of molecular biology with machine learning algorithms. This screening test can help detect cancer before symptoms appear. Peripheral blood mononuclear cells are isolated from blood samples, and gene expression anal

Immune Frame - Comprehensive Guide

Published April 9th, 2025 by Lisbeth Roy

Better Understanding of How to Use the Immune Frame The purpose of the Pre-Therapy Immune Frame is to: Provide a pre cellular RGCC therapy baseline Screen for high markers that could disqualify the person from being able to appropriately respond to cellular therapy. A pre-therapy Immune Frame should be ordered within three months of ordering a cellu

Lyme Disease: Comprehensive Approach

Published March 29th, 2025 by Lisbeth Roy

Understanding Lyme and Vector-Borne Infections Lyme disease and other vector-borne infections can persist within a host for life, often remaining asymptomatic for years. These microbes typically do not exceed the host's capacity to support them without triggering symptoms. However, symptoms can arise when the host-microbe balance is disrupted due to

OncoTrace Test - Comprehensive Guide

Published April 4th, 2025 by Lisbeth Roy

Comprehensive Guide to Understanding & Interpreting OncoTrace Test Results Purpose: Detects the presence of ALL types of malignant cells (CTCs) in circulation (whole blood) at a very low level of 1.3 CTC in 10 million WBCs or 1 CTC in 25 mL of whole blood. The OncoTrace test is used as a baseline for future comparison to assess therapy effective

Circulating Tumor Cells (CTCs) as a biomarker of relapse and metastasis A review of 21 patients with breast cancer (003)

Published February 17th, 2025 by Lisbeth Roy

Circulating Tumor Cells (CTCs) as a biomarker of relapse and metastasis: A review of 21 patients with breast cancer Zirkulierenden Tumorzellen (CTCs) als Biomarker für Rückfall und Metastase: Eine Überprüfung von 21 Patienten mit Brustkrebs Chatziioannou M.1, Apostolou P.1, Toloudi M.1, Ioannou E1, Retsas I.1 , R. Hammon2, N. Hembry4, U. Jacob3, A.

CIRCULATING TUMOR CELLS OR STEM TUMOR CELLS FROM PERIFERAL BLOOD AS A PROGNOSTIC MARKER FOR THE CLINICAL

Published February 18th, 2025 by Lisbeth Roy

I. Papasotiriou1,5 , M. Toloudi1 , M. Chatziioannou1 , P. Apostolou1, U. Jacob2, R. Hammon3, N. Hembry4,5 1 R.G.C.C - Research Genetic Cancer Centre Ltd., 115 M. Alexandrou Str, Filotas – Florina, Greece 2 AMC -Ursula Jacob GmbH – Klinik, Silberwaldstraβe 24, Dornstetten – Hallwangen, Freundenstadt, Deutschland 3 R.G.C.C –USA LLC, 6822 22nd Avenue N

Lab and Imaging FAQ

Published March 29th, 2025 by Lisbeth Roy

RGCC Lab Testing Oncotrace Purpose: Determines the origin of detected CTCs and tracks treatment response. Sample: 7-10 ml blood Use for: Identifying tumor origin, monitoring recurrence and monitoring therapeutic response to treatments. Oncotrail Purpose: Monitors CTC levels for specific cancer types (prostate, breast, colon, lung). Sample: 10 ml blo

Validated Research

Published February 20th, 2025 by Lisbeth Roy

Thank you for contacting RGCC-USA. Please find below the validation research requested. https://www.rgcc-group.com/wp-content/uploads/2020/07/International-Journal-of-Molecular-Sciences.pdf https://www.rgcc-group.com/wp-content/uploads/2020/03/CTC-mel-BMC-2020.pdf https://www.rgcc-group.com/wp-content/uploads/2019/10/Guadagni2019_Article_PrecisionOn

The PrecisionPath Method Handout

Published March 29th, 2025 by Lisbeth Roy

The PrecisionPath™ Method: A Root-Cause Approach to Adjunctive Cancer Care & Long-Term Wellness Personalized Adjunctive Functional Oncology for the Best Cancer Outcome What is the PrecisionPath™ Method? The PrecisionPath™ Method is a revolutionary functional oncology program that combines:✅ RGCC genetic testing & therapies for targeted cance

Vaccine Prep (ATA)

Published April 13th, 2025 by Lisbeth Roy

The Vaccine Prep (ATA) therapy by RGCC is an immune therapy that enhances the immune system's ability to recognize and destroy cancer cells. By utilizing cellular fragments from dying circulating tumor cells (CTCs), this therapy stimulates the activation and development of dendritic cells, which play a critical role in initiating a targeted immune r

RGCC questions

Published March 29th, 2025 by Lisbeth Roy

RGCC questions pulled from appts How long will the treatment last, and what does it include? Answer: 14 months: IV infusions (SOTs), and labs  Why is therapy rotation important? Answer: Rotating therapies helps prevent resistance and targets circulating tumor cells more effectively. How many times do I need to visit the clinic? Answer: Six visits ar

RGCC - BASIC PROTOCOL GUIDELINES TO CONSIDER - Comprehensive - 2022

Published April 5th, 2025 by Lisbeth Roy

RGCC BASIC PROTOCOL GUIDELINES – 9.1.22 As a practitioner, it is your responsibility to consider all of the factors that play a role in creating a personalized protocol for your patient. Factors to consider are: Current health status Health history Medical testing Imaging RGCC test results (CTC’s, stemness markers, gene expression, Conventional and

OFFER (RGCC) Cancer Assessment Women

Published April 6th, 2025 by Lisbeth Roy

Remote Blood Draw - Practitioner Guide

Published April 5th, 2025 by Lisbeth Roy

Remote Blood Draw – Practitioner Guide The Remote Blood Draw option is available to patients who live at a distance from their RGCC practitioners to avoid the time and expense of long-distance travel when only needing an RGCC blood draw. Simply follow the steps below: Sending a Kit to Your Patient: The in-portal Kits-Vials order form allows for an a

RGCC Orientation Guide

Published April 5th, 2025 by Lisbeth Roy

RGCC International North America RGCC International North America Contact Information: Customer Relations: Administrative questions Help placing test and therapy orders Help placing kit orders Shipping questions Portal and Order assistance Payment issues or refund requests Telephone: (800) 813-1372 Email Address: info@rgcc-international-northamerica

RGCC Testing Consumer Handout

Published March 29th, 2025 by Lisbeth Roy

What is RGCC? RGCC (Research Genetic Cancer Center) specializes in advanced cancer testing and personalized therapies to target your unique cancer biology. By analyzing circulating tumor cells (CTCs), genetic markers, and immune function, RGCC helps determine your most effective treatment options. Why Choose RGCC Testing? ✔ Personalized Approach – I

Beyond CLIA

Published April 6th, 2025 by Lisbeth Roy

Presentation Outline Overview of international QMS standards & guidelines CLSI ISO Comparison of CLSI, ISO and CLIA Questions to consider Questions to Consider What international QMS standards/guidelines apply to clinical laboratories? How do these standards/guides differ from CLIA? How are they being used within and outside of USA? What are the

RGCC substance replacements in Onconomics PlusExtractsExtracts

Published February 20th, 2025 by Lisbeth Roy

https://static.helpjuice.com/helpjuice_production/uploads/upload/image/22858/direct/1740078178813/RGCC%20substance%20replacements%20in%20Onconomics%20PlusExtractsExtracts%20.pdf

Blood Draw Instructions

Published April 8th, 2025 by Lisbeth Roy

Blood Draw Instructions - Multi-Fly Needle Method (New Kit: 30 ml glass vials) Sterilize area. Insert multi-fly needle and stabilize. Fit adapter to other/open end. Remove inner circle of aluminum foil to expose rubber stopper on 30 ml vial in preparation for draw. DO NOT remove the entire foil cap. Collect 2-3 ml of blood in small vacutainer tube a

Clavic-Q-RE Guidelines.v2

Published April 12th, 2025 by Lisbeth Roy

Disclaimer: This document is intended exclusively for RGCC practitioners as an informational resource and guide to support the understanding and application of therapy protocols. It is not intended for use as medical advice for patients, nor should it be shared directly with patients or used as a substitute for individualized patient care. Please as

Karnofsky Scale

Published February 18th, 2025 by Lisbeth Roy

The Karnofsky scale was devised by two American doctors in the 1940s (David Karnofsky and Joseph Burchenal) as an attempt to try and measure the more ‘subjective’ side of the outcome of cancer treatment. In fact, the scale relates purely to physical ability and covers 11 points, from normal health to death, each scored as a percentage. The scale is:

RGCC Methodology and Supporting Literature

Published February 20th, 2025 by Lisbeth Roy

Below is a link to a zip drive with 18 articles and abstracts relative to the validity and efficacy of RGCC testing and methodology.  https://rgcc.zendesk.com/attachments/token/h2fdpZbsIiWV49ydh7SBjC6ty/?name=RGCC+Literature+for+Validity+and+Efficacy+of+RGCC+Testing+and+Methodology.zip These are all available in the "Research" section of the interna

Rgcc tested chemotherapeutic agents

Published April 9th, 2025 by Lisbeth Roy

Alkyliating Agents Iinhibitors of Topoisomerase I Tumor Suppressor Genes i (cont.) Biological Modifiers Cisplatin CPT11 Gamma_GC Cetuximab Carboplatin Topotecan TP Erlotinib Cyclophosfamide Gimatecan NP Bevacizumab Ifosfamide Iinhibitors of Topoisomerase II UP Rituximab dacarbazine Doxorubicin DPD Goserelin oxaliplatin Liposomal_doxorubicin p27 5-az

Onco D clare Flowchart

Published February 18th, 2025 by Lisbeth Roy

General Cancer Markers

Published February 18th, 2025 by Lisbeth Roy

General Cancer Markers Alpha-Fetoprotein (AFP) Sensitivity: ~60–80% for hepatocellular carcinoma (HCC). Higher sensitivity in advanced disease; lower in early stages. Carcinoembryonic Antigen (CEA) Sensitivity: ~30–50% for colorectal cancer at early stages, up to 70–80% in advanced stages. Limited utility for early detection. Lactate Dehydrogenase (

RGCC Tested Chemotherapeutic Agents

Published February 20th, 2025 by Lisbeth Roy

Alkyliating Agents Iinhibitors of Topoisomerase I Tumor Suppressor Genes i (cont.) Biological Modifiers Cisplatin CPT11 Gamma_GC Cetuximab Carboplatin Topotecan TP Erlotinib Cyclophosfamide Gimatecan NP Bevacizumab Ifosfamide Iinhibitors of Topoisomerase II UP Rituximab dacarbazine Doxorubicin DPD Goserelin oxaliplatin Liposomal_doxorubicin p27 5-az

RGCC Accreditation, facilities, capabilities and publications 7.23.24

Published February 18th, 2025 by Lisbeth Roy

RGCC International - Driven by Science, Experience, Vision RGCC International is a specialized medical genetics laboratory, established in 2004, by genetics pioneer Dr. Ioannis Papasotiriou, MD, PhD, SCym. His commitment to personalized cancer care and unwavering belief in the power of a patient’s genes, has fueled Dr. Papasotiriou’s vision to creat

Delivering a Cancer diagnosis

Published March 29th, 2025 by Lisbeth Roy

Delivering a Cancer diagnosis… When delivering such sensitive information, it's essential to approach the conversation with empathy, reassurance, and a clear explanation of the benefits of early detection using RGCC testing, even when the origin of the cancer is unknown. Here’s what I would convey to the patient: Acknowledging the Emotional Impact I

SOT Therapy - Comprehensive Guide - Cancer Micro June 1st, 2024

Published April 5th, 2025 by Lisbeth Roy

SOT therapy What is SOT therapy? Supportive Oligonucleotide Therapy (SOT) is a process that enables the RGCC lab to identify the specific gene sequences of different targets such as cancer, Lyme, and various viruses and design a specific oligonucleotide therapy. The SOT is uniquely tailored to each patient’s needs. It is a small oligonucleotide whic

OncoTrace Results

Published April 11th, 2025 by Lisbeth Roy

Blood Draw Comprehensive Guide RGCC

Published April 8th, 2025 by Lisbeth Roy

Pre- and post-blood draw guidelines The guidelines recommended below were developed over multiple years of research by RGCC. The main purpose of these recommendations is to allow the lab to find more cancer cells, viruses, and/or Lyme in the patient’s blood sample, allowing for the most accurate test results, and most effective therapies. Q: How lon

CONSENT RGCC Cancer Labs Testing

Published April 6th, 2025 by Lisbeth Roy

Cancer Testing Baseline and Monitoring

Published February 17th, 2025 by Lisbeth Roy

RGCC Testing: Baseline and Monitoring Cancer Testing Step 1: Onco-D-Clare - to determine if the immune system picks up the conversion from normal to abnormal at the cellular level. No pre-requisites for testing Step 2: Oncotrace - to determine the presence of CTCs and stemness markers. Onconomics Plus- to determine the specific genetics of the cance

Detection of Circulating Tumor Cells in Patients with Breast Prostate Pancreatic Colon and Melanoma Cancer A Blinded Comparative Study Using Healthy Donors 3

Published February 18th, 2025 by Lisbeth Roy

Abstract Cancer is a diverse disease characterized by abnormal cell growth and the ability to invade or spread to other parts of the body. Because the yearly cancer rate is increasing, an important area for cancer researchers is to improve the ability to detect and treat cancer early. The current study analyzes the potential of flow cytometry to be

Clavic-Q-RE

Published April 13th, 2025 by Lisbeth Roy

The Clavic-Q-RE therapy by RGCC is a cutting-edge immune therapy that combines the power of both innate and adaptive immunity to destroy cancer cells and provide long-term protection against recurrence. This autologous adoptive cellular therapy harnesses the patient’s own immune cells, enhancing their ability to fight cancer through a multi-faceted

Studies showing benefit of RGCC testing and recommended therapy

Published February 20th, 2025 by Lisbeth Roy

https://www.rgcc-group.com/wp-content/uploads/2020/07/International-Journal-of-Molecular-Sciences.pdf https://www.rgcc-group.com/wp-content/uploads/2020/03/CTC-mel-BMC-2020.pdf https://www.rgcc-group.com/wp-content/uploads/2019/10/Guadagni2019_Article_PrecisionOncotherapyBasedOnLiq.pdf

ECOG Performance Status

Published February 18th, 2025 by Lisbeth Roy

These scales and criteria are used by doctors and researchers to assess how a patient’s disease is progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis. They are included here for health care professionals to access. Grade ECOG 0 Fully active, able to carry on all pr

TREATMENT (RGCC) Cancer Supportive Program

Published April 6th, 2025 by Lisbeth Roy

RGCC Accreditations - July 2024

Published February 18th, 2025 by Lisbeth Roy

RGCC International - Driven by Science, Experience, Vision RGCC International is a specialized medical genetics laboratory established in 2004 by genetics pioneer Dr. Ioannis Papasotiriou, MD, PhD, SCym. His commitment to personalized cancer care and unwavering belief in the power of a patient’s genes has fueled Dr. Papasotiriou’s vision to create p

Dendritic Cell Therapy - Comprehensive Guide

Published April 3rd, 2025 by Lisbeth Roy

Dendritic cell therapy What are DENDRITIC CELLS? Dendritic Cells (DCs) are known as antigen presenting cells. They are special key regulators of the Immune system capable of activating theT-Cells and stimulating the growth and differentiation of B-Cells. Dendritic cells identify specific protein markers known as peptides on the surface of foreign or

CTC Viability, Isolation, and Identification - July 2024

Published February 18th, 2025 by Lisbeth Roy

A full library of publications is available on the RGCC website: https://rgcc-international.com/published-articles/ CTC Viability, Isolation, and Identification Viability: Taking under consideration the fragility of Circulating Tumour cells, RGCC’s sample collection and shipping methods are based on studies that have been performed and published dem

Early Diagnose of the Limited Number of CTCS

Published February 18th, 2025 by Lisbeth Roy

Aim The aim of this study was to show whether the early diagnoses of the limited circulating tumor cells can contribute to an effective treatment of the disease with the already established drugs used in chemotherapies. Materials and methods There were studied: 38 patients with breast cancer (men and women, stages I-IV), 21 men with prostate cancer

Why Diagnosis is Important

Published February 20th, 2025 by Lisbeth Roy

RCCC International – North America Why is it important to use the correct cancer diagnosis for the RCCC tests? The representativeness of the analysis relies on having the correct cancer type and stage information. Different cancer types expand optimally on specific hydrogels, and various stages require unique growth factors within the media, as the f

Understanding FDA approval and RGCC

Published February 20th, 2025 by Lisbeth Roy

The mRNA technology used for producing RGCC therapies is approved in Europe by EMA (European Medicines Agency), the equivalent to the FDA here in the US, as ATMPs (Advanced Therapy Medicinal Products) ATMPs are advanced therapeutics for human use that are based on genes, tissues, or cells. ATMPs offer groundbreaking new opportunities for the treatme

RGCC Tested Natural Substances and Suppliers

Published April 9th, 2025 by Lisbeth Roy

Natural Substance and Suppliers 1. Agaricus Blazei Murill Power Full Health Foods Corp. 215-1 Hiraoka Shinanomachi Kamiminochigun Nagano-ken, 389- 1315 JapanPhone: 81(0)26-255-5581 Fax: 81(0)26-255-6733 Agaricus blazei Murill (subrufescens) is an edible, medicinal mushroom with characteristic, somewhat sweet taste and the fragrance of almonds, that

1000mg melatonin and untreatable cancer

Published April 7th, 2025 by Lisbeth Roy

A Preliminary Phase-2 Study with very High- Dose of Melatonin (1000 mg/day) in Untreatable Advanced Cancer Patients Already Progression on Previous Palliative Therapy with High-Dose Melatonin Abstract It is known since more than 50 years that the pineal gland plays a fundamental role in the natural biological resistance against cancer onset and grow

Summary ODC-OT-Galleri 050124

Published February 20th, 2025 by Lisbeth Roy

RGCC Oncotrace RGCC Onco-D-clare Galleri Liquid Biopsy Liquid Biopsy Liquid Biopsy For established cancer diagnosis or anyone with a history of cancer or cancer in remission, and cancer surveillance to detect recurrence For healthy population, with no history of cancer, but with risks due to family history or vulnerability from environmental toxin e

Managing Lyme and other Tickborne Illnesses

Published March 29th, 2025 by Lisbeth Roy

WELCOME! Welcome to the sixteenth edition of the “Guidelines”. Amazingly, this edition is not only the sixteenth in the series, but as the first edition appeared in 1984, this reflects twenty four years of effort! Since the last edition, enough new information has become available to justify this revision. New insights regarding co-infections, tests

RGCC- INTRO TO TESTS

Published April 8th, 2025 by Lisbeth Roy

Introduction to RGCC’s Tests Array Comparative Hybridization (aCGH) Missing primary origin or Missing Knowledge? Identification of the origin of the primary tumor Based on DNA Analysis of CTCs/CSCs for detection of chromosomal abnormalities Non-invasive (Blood Sample) All types of cancer Needless interpretation Final results in 3-4 weeks Example Chr

Clavic-Q-RE Guidelines.v2

Published April 3rd, 2025 by Lisbeth Roy

Disclaimer: This document is intended exclusively for RGCC practitioners as an informational resource and guide to support the understanding and application of therapy protocols. It is not intended for use as medical advice for patients, nor should it be shared directly withpatients or used as a substitute for individualized patient care. Please ass

How to Send Additional Substances

Published February 18th, 2025 by Lisbeth Roy

In addition to the 50 natural substances automatically tested in the Onconomics Extracts, Onconomics Extracts +, and Onconomics Plus panels, you can customize the panel by selecting 5 additional substances to be tested at no additional charge. Customization can be expanded if you would like to have more than 5 additional substances tested. Substance

More info about Onco D clare V2

Published February 18th, 2025 by Lisbeth Roy

https://static.helpjuice.com/helpjuice_production/uploads/upload/image/22858/direct/1739905248081/More-info-about-Onco-D-clare_V2.pdf

CTC Conversion Formula

Published February 18th, 2025 by Lisbeth Roy

Cells/mL vs Cells/7.5 mL vs Cells/6.5 mL Sarcoma Conversion Formula: Cells/mL = ((cells/6.5 mL x 5)/sqr2) x0.21 Example 1: Converting 4.6 cells/6.5 mL to cells/mL ((4.6 x 6.5)/1.414) x 0.21 = 4.4 cells/mL Example 2: Converting 4.4 cells/mL to cells/6.5 mL ((4.4/0.21) x 1.414)/6.5 = 4.6 cells/6.5 mL Breast Cancer Conversion Formula: Cells/mL = ((cell

Karnofsky Scale Information Sheet

Published April 4th, 2025 by Lisbeth Roy

Karnofsky Scale The Karnofsky scale was devised by two American doctors in the 1940s (David Karnofsky and Joseph Burchenal) as an attempt to try and measure the more ‘subjective’ side of the outcome of cancer treatment. In fact the scale relates purely to physical ability and covers 11 points, from normal health to death, each scored as a percentage

Follow Up Forms - Required

Published April 8th, 2025 by Lisbeth Roy

PRE and POST Q RESTRAIN INFUSION PROTOCOL TO REDUCE HERX EFFECT

Published March 28th, 2025 by Lisbeth Roy

Pre-Q Restrain Infusion (Start one week prior): Phosphatidylcholine: Product: Phosphatidylcholine by BodyBio Dosage: 2 capsules twice daily with food N-Acetyl Cysteine (NAC): Product: N-Acetyl Cysteine by Pure Encapsulations Dosage: 600 mg (1 capsule) daily on an empty stomach Mineral Supplement: Product: MinRex by Xymogen Dosage: 2 capsules twice d

RGCC Test Descriptions

Published April 8th, 2025 by Lisbeth Roy

RGCC Baseline and Follow-Up Tests: OncoTrace: Used as a BASELINE and FOLLOW-UP tool to determine starting point, and monitoring effectiveness oftreatment protocols May also be used for long-term monitoring following successful treatment for early detection of recurrence Detects presence of ALL cancer types (except those of CNS origin) Detects the pr

General Questions About the PrecisionPath ™ Method; Q RESTRAIN, RGCC Testing, etc.

Published March 28th, 2025 by Lisbeth Roy

What does Q RESTRAIN (Supportive Oligonucleotide Therapy)? Q RESTRAIN (Supportive Oligonucleotide Therapy) is a treatment designed to target the genetic instructions that cancer cells use to multiply. By blocking or disrupting these instructions, Q RESTRAIN prevents cancer cells from growing and spreading. Over time, this process can cause the cance

Therapy Descriptions

Published February 20th, 2025 by Lisbeth Roy

RGCC International Test Descriptions RGCC Screening test:  Onco-D-clare: Onco-D-clare is a cancer screening test based on the interaction of molecular biology with machine learning algorithms. This screening test can help detect cancer before symptoms appear. Peripheral blood mononuclear cells are isolated from blood samples, and gene expression ana

RGCC Available Additional Substances

Published February 18th, 2025 by Lisbeth Roy

https://static.helpjuice.com/helpjuice_production/uploads/upload/image/22858/direct/1739906255612/RGCC%20_Available_Additional_Substances.pdf

Pre & Post Blood Draw Guidelines

Published April 8th, 2025 by Lisbeth Roy

The below recommended guidelines were developed over the past years of research by RGCC. The main purpose of these recommendations is to allow the lab to find more cancer cells, viruses and/or Lyme in the patient’s blood sample, allowing for the most accurate test results, and most effective therapies. Q: How long should you wait to draw blood after

RGCC International North America Orientation Guide

Published February 20th, 2025 by Lisbeth Roy

RCCC International North America Contact Information: Customer Relations: Administrative questions Help placing test and therapy orders Help placing kit orders Shipping questions Portal and Order assistance Payment issues or refund requests Telephone: (800) 813-1372 Email Address: info@rgcc-international-com Clinical Support: Technical and clinical

Why CTC can be Zero with an Advanced Cancer Patient

Published February 20th, 2025 by Lisbeth Roy

All tests have limits, there is no 100% in any test. For instance, in order to even start the process, RGCC needs to identify and isolate the CTCs before proceeding to the next step of analysis. There are a few cases that CTC may not be identified hence the process will not proceed and declared as 0 CTCs. Common reasons for this occurring are as fol

Literature References for Validity, Precision, Accuracy, and Methodology of RGCC Testing

Published February 18th, 2025 by Lisbeth Roy

Liquid Biopsy Review Articles CTC Detection and Isolation: https://rgcc-international.com/wp-content/uploads/2019/06/Osaka.Japan_.Circulating- Tumor-Cells-Challenges-in-Detection-and-Isolation.pdf CTC Detection and Isolation using Negative Selection Method: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631028/ https://www.intechopen.com/chapters/518

Flow Cytometric Detection of Circulating Tumor Cells in Breast Cancer Patients: A Blinded Study

Published February 18th, 2025 by Lisbeth Roy

Abstract Circulating tumor cells are cells that detach from the primary tumor site and migrate to the bone marrow or other tissues where they can initiate a metas- tatic site. Liquid biopsies are an emerging tool in the past decades that enables us to detect Circulating Tumor Cells in patients’ blood. Flow cytometry is a powerful tool used in liquid

ACH

Published April 9th, 2025 by Lisbeth Roy

The ArrayCGH RGCC test is an advanced diagnostic tool used when the primary origin of a tumor is unknown. By analyzing chromosomal abnormalities, this test provides valuable insights into potential tumor origins, guiding further diagnostic and therapeutic decisions. Here’s what it offers and how it works: How the ArrayCGH RGCC Test Works Blood Sampl

MetaStat

Published April 9th, 2025 by Lisbeth Roy

The Metastat test by RGCC is a sophisticated diagnostic tool designed to predict the likelihood of secondary tumor development (metastasis) and identify its potential location. By analyzing blood-borne markers, it provides critical insights into cancer progression, helping guide proactive treatment and monitoring strategies. Here’s how it works and

InVyomma Plus

Published April 9th, 2025 by Lisbeth Roy

The InVyomma Plus Diagnostic Test by RGCC is a comprehensive molecular diagnostic tool designed to analyze circulating tumor cells (CTCs) and cancer stem cells (CSCs) in the bloodstream. This test provides insights into the genetic, epigenetic, and proteomic profile of cancer, offering actionable data to guide personalized treatment strategies. Here

Quick Guide for Immune Frame and Vaccine Therapy

Published April 9th, 2025 by Lisbeth Roy

Purpose of the Immune Frame Test Provides a baseline immune status before starting RGCC cellular therapy. Screens for high-risk markers that may impact therapy effectiveness. It helps in monitoring immune response post-therapy every 6 months. Pre-Therapy Testing Requirements Order within 3 months of planned cellular therapy. A CTC test is also requi

CambiSEQ

Published April 9th, 2025 by Lisbeth Roy

The CAMBISeq test (Cancer Analysis Mutational Burden Instability Sequencing) is a cutting-edge diagnostic tool that uses Next Generation Sequencing (NGS) to analyze the genetic profile of cancer. This advanced test provides insights into mutations and genetic variations that can guide personalized treatment decisions, particularly for immunotherapy

Onco-D-clare Flowchart

Published April 9th, 2025 by Lisbeth Roy

OncoTrail

Published April 9th, 2025 by Lisbeth Roy

The OncoTrace test by RGCC is a versatile diagnostic tool designed to detect and monitor cancer through the presence of circulating tumor cells (CTCs) in the bloodstream. It serves as both a baseline assessment and a follow-up tool to evaluate the effectiveness of treatment protocols and detect potential recurrence after successful treatment. Here's

ImmunoFrame

Published April 9th, 2025 by Lisbeth Roy

The Immune Frame test by RGCC is a specialized diagnostic tool used to evaluate a patient’s immune system status and determine their eligibility for cellular therapies. It provides critical insights into the immune system's function and readiness, helping establish a baseline for treatment and monitoring therapeutic response over time. Here’s what i

Onconomics Plus

Published April 9th, 2025 by Lisbeth Roy

The OncoTrail test by RGCC is a specialized diagnostic tool designed for use when the primary tumor origin is already known. It provides detailed insights for specific cancer types, serving as both a baseline assessment and a follow-up tool to monitor treatment effectiveness and detect recurrence. Here’s how it works and what it offers: How OncoTrai

ABCG2 Inhibitors Sites And Lists For

Published February 17th, 2025 by Lisbeth Roy

Sights and Lists for ABCG2 Inhibitors The list below is a large number of known and often used natural ingredients that are well known to work through the ABCG2 inhibition pathway. MDR1—USE ABCG2 INHIBITORS—MOSTLY THE FLAVONOIDS—i.e. QUERCETIN, CURCUMIN, ALLICIN, CAPSAICIN, GENISTEIN, GINGEROL, HESPERETIN (FLAVANONES) - TANGELO, ORANGE JUICE, TANGER

Chemo-SNiP

Published April 9th, 2025 by Lisbeth Roy

The ChemoSNiP test by RGCC is a cutting-edge diagnostic tool designed to analyze how a patient’s genetic profile influences their response to various drugs. It focuses on pharmacokinetics—how the body metabolizes medications—and provides invaluable insights to guide personalized cancer treatment. Here’s how it works and its key benefits: How the Che

RGCC Testing Chemotherapeutics and Natural Substances

Published February 18th, 2025 by Lisbeth Roy

Alkyliating Agents Iinhibitors of Topoisomerase I Tumor Suppressor Genes i (cont.) Biological Modifiers Cisplatin CPT11 Gamma_GC Cetuximab Carboplatin Topotecan TP Erlotinib Cyclophosfamide Gimatecan NP Bevacizumab Ifosfamide Iinhibitors of Topoisomerase II UP Rituximab dacarbazine Doxorubicin DPD Goserelin oxaliplatin Liposomal_doxorubicin p27 5-az

Acetyl L Carnatine Downregulates CXCR4 and CXCR12 and VEGF

Published February 17th, 2025 by Lisbeth Roy

Baci et al. Journal of Experimental & Clinical Cancer Research (2019) 38:464 https://doi.org/10.1186/s13046-019-1461-z Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies Denisa Baci1†, Antonino Bruno2†, Caterina Cas

Immune Frame - Comprehensive Guide

Published April 4th, 2025 by Lisbeth Roy

Immune frame Better Understanding of How to Use the Immune Frame The purpose of the Pre-Therapy Immune Frame is to: Provide a pre cellular RGCC therapy baseline Screen for high markers that could disqualify the person from being able toappropriately respond to cellular therapy. A pre-therapy Immune Frame should be ordered within three months of orde

Dendritic Cell Therapy - Comprehensive Guide

Published April 13th, 2025 by Lisbeth Roy

What are DENDRITIC CELLS? Dendritic Cells (DCs) are known as antigen presenting cells. They are special key regulators of the Immune system capable of activating the T-Cells and stimulating the growth and dierentiation of B-Cells. Dendritic cells identify specific protein markers known as peptides on the surface of foreign or invading cells. DCs the

Dendritic Cell Therapy

Published April 13th, 2025 by Lisbeth Roy

The Dendritic Cell (DC) therapy by RGCC is a groundbreaking immune therapy designed to enhance the body’s ability to identify and destroy cancer cells while providing long-lasting immunity. By leveraging the natural function of dendritic cells, this therapy stimulates a powerful and targeted immune response against cancer. Here’s an overview of how

iPSC Therapy - Comprehensive Guide

Published April 4th, 2025 by Lisbeth Roy

iPSC Therapy What are IPSC cells? The IPSC cells (AKA induced pluripotent stem cells) are hematopoietic stem cells. Their role is to give rise to other blood cell types. They are normally found in the bone marrow of (pelvis, femur, sternum), umbilical cord blood and peripheral blood. They are quiescent in nature which gives them the ability to survi

iPSC Therapy - Comprehensive Guide

Published April 13th, 2025 by Lisbeth Roy

What are IPSC cells? The IPSC cells (AKA induced pluripotent stem cells) are hematopoietic stem cells. Their role is to give rise to other blood cell types. They are normally found in the bone marrow of (pelvis, femur, sternum), umbilical cord blood and peripheral blood. They are quiescent in nature which gives them the ability to survive in the hyp

RGCC-Presentation_SOT_TLMS

Published April 13th, 2025 by Lisbeth Roy

Q-Restrain Therapy (Formally SOT Therapy)

Published April 13th, 2025 by Lisbeth Roy

Your browser does not support HTML5 video.

Cancer Care 2024 03 29 v1

Published February 18th, 2025 by Lisbeth Roy

https://static.helpjuice.com/helpjuice_production/uploads/upload/image/22858/direct/1739900672004/Cancer-Care-2024-03-29-v1.pdf

CTC Isolation Technology

Published February 18th, 2025 by Lisbeth Roy

How RGCC’s CTC isolation technology is unique Cancer is a systemic disease, especially in advanced cases. This means it can spread to diâerent locations in the body and exhibit variations in behavior at each site. Circulating tumor cells (CTCs) serve as a crucial link between the primary tumor and metastatic sites. We know that CTCs themselves are r

SOT as an Alternative Treatment Option in Cancer

Published April 13th, 2025 by Lisbeth Roy

Abstract. Background/Aim: An early evaluation concerning the effectiveness of supportive oligonucleotide therapy (SOT) in cancer as a monotherapy and in combination with other types of treatment. Patients and Methods: This study evaluated the clinical condition and performance status (Karnofsky-Index) of 95 patients, post-SOT administration. Further

IV Poly-MVA Protocol for Integrative Oncology

Published March 28th, 2025 by Lisbeth Roy

Poly-MVA is widely used in integrative oncology and functional medicine for mitochondrial support, antioxidant defense, and cellular repair. Below is a general IV Poly-MVA protocol based on clinical use in cancer support and chronic disease management. IV Poly-MVA Protocol for Integrative Oncology Purpose: Mitochondrial support: Enhances ATP product

Personalized IV Schedule

Published March 28th, 2025 by Lisbeth Roy

Based on the RGCC Onconomics Plus Report, this plan is designed to: ✔ Target tumor vulnerabilities (sensitive pathways)✔ Block angiogenesis & metastasis (VEGF, FGF, PDGF, MMP)✔ Modulate immune function (reduce inflammation & tumor growth signals)✔ Support detoxification & mitochondrial function 📅 IV Therapy Schedule (12-Week Cycle) IV Fr

Q-REstrain Guidelines.v2

Published April 13th, 2025 by Lisbeth Roy

Disclaimer: This document is intended exclusively for RGCC practitioners as an informational resource and guide to support the understanding and application of therapy protocols. It is not intended for use as medical advice for patients, nor should it be shared directly with patients or used as a substitute for individualized patient care. Please as

SOT - Herx Help -Pre and Post -11.11.22 - Copy

Published April 13th, 2025 by Lisbeth Roy

*Phosphatidyl Choline  Dose: 2 pills twice a day with food *NAC (600 mg)Dose: 1 pill daily on an empty stomach *MinREX (other type of mineral ok)Dose: 2 pills twice a day with food GI DETOX by Bio-Botanical ResearchDose: 2 pills daily on an empty stomach. Do not take with other supplements. Drink full glass of water with this product. Multi -Immune

OncoTrace Test - Comprehensive Guide

Published April 8th, 2025 by Lisbeth Roy

Comprehensive Guide to Understanding & Interpreting OncoTrace Test Results Purpose: Detects the presence of ALL types of malignant cells (CTCs) in circulation (whole blood) at a very low level of 1.3 CTC in 10 million WBCs or 1 CTC in 25 mL of whole blood. The OncoTrace test is used as a baseline for future comparison to assess therapy effective

Allopathic Treatment of Lyme

Published March 31st, 2025 by Lisbeth Roy

MODULE 3: ALLOPATHIC TREATMENT OF LYME DISEASE Lesson 1: General Considerations of Antibiotic TherapyTo antibiotic or not to antibiotic?What to expectHerxheimer reactionsSide effects of antibioticsStrategies for success Lesson 2: Antibiotic Therapy For Acute Lyme Lesson 3: Antibiotic Therapy For Chronic Lyme Lesson 4: Antibiotic Therapy for Co-infec

Blood Draw Quantities Guide 01.01.2023

Published April 8th, 2025 by Lisbeth Roy

SINGLE TEST Sample Size Vials aCGH 7-10ml 1 CAMBISeq 7-10ml 1 ChemoSNiP 7-10ml 1 ImmuneFrame 15-25ml 1 Metastat 7-10ml 1 OncoCount 7-10ml 1 Onconomics 15-25ml 1 Onconomics Extracts 15-25ml 1 Onconomics Plus 15-25ml 1 OncoTrail 7-10ml 1 OncoTrace 7-10ml 1 PrimeSPOT 7-10ml 1 PaLDiSPOT 7-10ml 1 PrediSPOT 7-10ml 1 SNPs 7-10ml 1 SINGLE THERAPY Sample Siz

Intro to RGCC, Tests, and Therapies

Published April 8th, 2025 by Lisbeth Roy

A global network of practitioners RGCC operates in over 20 countries With bases in five continents Our laboratories worldwide Equipped with world-leading technology and staffed by experts in their fields RGCC Switzerland RGCC Greece RGCC Central Europe RGCC India Why RGCC? RGCC’s CTC Tests are Unique & Empowering 3 main CTC panels - Oncocount, O

SOT Add on process - 1.20.23

Published April 8th, 2025 by Lisbeth Roy

SOT Add on process For add-on SOT orders, it's a two-step process. First, you place the order through the Portal. Second, you submit the Order Confirmation Document via email to the lab (medical@rgcc-genlab.com) with a cc to Info@rgcc-international-northamerica.com for processing. Once the order has been received by the lab, they will send you a con

Onco-D-Clare

Published April 9th, 2025 by Lisbeth Roy

The Onco-D-Clare test by RGCC is an advanced cancer screening tool that combines molecular biology with machine learning algorithms to detect cancer with remarkable precision, even before symptoms appear. Here’s how the test works: Blood Sample Collection A small blood sample is drawn from the individual and prepared for analysis. This non-invasive

Remote Blood Draw - Practitioner Guide

Published April 8th, 2025 by Lisbeth Roy

The Remote Blood Draw option is available to patients who live at a distance from their RGCC practitioners to avoid the time and expense of long-distance travel when only needing an RGCC blood draw. Simply follow the steps below: Sending a Kit to Your Patient: The in-portal Kits-Vials order form allows for an alternate shipping address so you can dr

RGCC Tested Chemotherapeutic Agents

Published April 11th, 2025 by Lisbeth Roy

Alkyliating Agents Iinhibitors of Topoisomerase I Tumor Suppressor Genes i (cont.) Biological Modifiers Cisplatin CPT11 Gamma_GC Cetuximab Carboplatin Topotecan TP Erlotinib Cyclophosfamide Gimatecan NP Bevacizumab Ifosfamide Iinhibitors of Topoisomerase II UP Rituximab dacarbazine Doxorubicin DPD Goserelin oxaliplatin Liposomal_doxorubicin p27 5-az

OncoTrace

Published April 9th, 2025 by Lisbeth Roy

The OncoTrace test by RGCC is a versatile diagnostic tool designed to detect and monitor cancer through the presence of circulating tumor cells (CTCs) in the bloodstream. It serves as both a baseline assessment and a follow-up tool to evaluate the effectiveness of treatment protocols and detect potential recurrence after successful treatment. Here's

Biomarkers Reference Guide

Published April 10th, 2025 by Lisbeth Roy

Growth Factors Proliferation Stimuli (6/19) P180 - Ribosome-binding protein 1 or RRBP1  RRBP1 is detected as a ribosome-binding protein located on the rough ER and associated with unfolding protein response. It is upregulated in a wide variety of cancer cells. RRBP1 could alleviate ER stress and help cancer cells survive. Function is pre-protein for

RGCC Tested Natural Substances

Published April 10th, 2025 by Lisbeth Roy

Natural Substance and Suppliers 1. Agaricus Blazei Murill Power Full Health Foods Corp. 215-1 Hiraoka Shinanomachi Kamiminochigun Nagano-ken, 389- 1315 JapanPhone: 81(0)26-255-5581 Fax: 81(0)26-255-6733 Agaricus blazei Murill (subrufescens) is an edible, medicinal mushroom with characteristic, somewhat sweet taste and the fragrance of almonds, that

Immune Frame - Patient Guide

Published April 10th, 2025 by Lisbeth Roy

Better Understanding of How to Use the Immune Frame The purpose of the Pre-Therapy Immune Frame is to: Provide a pre cellular RGCC therapy baseline Screen for high markers that could disqualify the person from being able to appropriately respond to a cellular therapy. A pre-Immune Frame should be ordered within three months of ordering a cellular th

Onconomics Plus Results

Published April 11th, 2025 by Lisbeth Roy

Diagnosing Lyme Disease

Published April 2nd, 2025 by Lisbeth Roy

MODULE 2: DIAGNOSING LYME DISEASE Lesson 1: Stages of Lyme disease Early localized Early disseminated Chronic Lesson 2: Differential Diagnosis – The Great Imitator Is Lyme Auto-immune? Lesson 3: Signs and Symptoms of Lyme and Co-infections Lesson 4: Testing for Lyme disease Direct tests Indirect tests Lesson 5: Testing for Co-infections Lesson 6: Kn

Response to Therapies Not Being FDA Approved

Published April 11th, 2025 by Lisbeth Roy

Response to Therapies Not Being FDA Approved The mRNA technology used for producing RGCC therapies is approved in Europe by EMA (European Medicines Agency), the equivalent to the FDA here in the US, as ATMPs (Advanced Therapy Medicinal Products) ATMPs are advanced therapeutics for human use that are based on genes, tissues, or cells. ATMPs offer gro

Lyme medication Summary- common doses

Published April 2nd, 2025 by Lisbeth Roy

MEDICATION SUMMARY - COMMON DOSAGES Penicillins: Amoxicillin 1000mg 3-6 daily Augmentin XR 2000mg 2x daily Bicillin LA 0.9 mill 2 vials injected IM 3x weekly Cephalosporins: Cefuroxime 500mg 3x daily Ceftriaxone 2 gram 2 grams twice daily IV 4 days/week Cefdinir 600mg 2x daily Macrolides: Azithromycin 500mg 1x daily Clarithromycin 500mg 2x daily Tel

Vaccine Prep - Patient Guide

Published April 10th, 2025 by Lisbeth Roy

What is VACCINE PREP THERAPY? RGCC’s Vaccine Prep Therapy uses tumor cell antigens that are produced from the patients’ isolated circulating tumor cells. Tumor cells from each patient potentially carry gene mutations encoding for unique TAAs that are important in stimulating effective and long-lasting anti-tumor responses in thepatient. Tumor cells

VAXO-Q-RE - Patient Guide

Published April 10th, 2025 by Lisbeth Roy

What is VAXO-Q-RE Therapy? VAXO-Q-RE is best described as an Autologous Adoptive Cellular Therapy. It consists of the basic players of innate and adaptive immunity, i.e., macrophages and Natural Killer cells (innate immune cells) and activated Dendritic Cells, T cells and antibody producing plasma cells (adaptiveimmune cells). Innate immune cells ar

Therapies Algorythm-Flowchart 1.25.22

Published April 11th, 2025 by Lisbeth Roy

iPSC Therapy - Patient Guide

Published April 10th, 2025 by Lisbeth Roy

What are IPSC cells? The IPSC cells (AKA induced pluripotent stem cells) are hematopoietic stem cells. Their role is to give rise to other blood cell types. They are normally found in the bone marrow of (pelvis, femur, sternum), umbilical cord blood and peripheral blood. They are quiescent in nature which gives them the ability to survive in the hyp

Test & Therapy Descriptions

Published April 11th, 2025 by Lisbeth Roy

RGCC International Test Descriptions RGCC Screening test: Onco-D-clare: Onco-D-clare is a cancer screening test based on the interaction of molecular biology with machine learning algorithms. This screening test can help detect cancer before symptoms appear. Peripheral blood mononuclear cells are isolated from blood samples, and gene expression anal

Therapy Follow-Up Questionnaire

Published April 11th, 2025 by Lisbeth Roy

Immune Frame Results

Published April 11th, 2025 by Lisbeth Roy

REPORT SUMMARY The ELISA assay results of the patient, show that there is down-regulation of immunity. According to the ELISA analysis the deactivation of the immunity is based on overproduction of relevant factors like CTLA4 Laboratory Process Serum isolation from 8ml of whole blood with centrifugation. Specific immunity activation/suppression cyto

lyme-disease-ebook

Published April 2nd, 2025 by Lisbeth Roy

FROM PAIN TO PURPOSE: HEATHER'S STORY “Why God? Why? What is the purpose of Heather’s suffering? Why isn’t she well? Why can’t she get better?” Those were some of the thoughts I constantly struggled with as I stood by and watched my wife’s health fall apart. There were many times that I questioned what was happening. I felt powerless and afraid. I c

SOT integrity control verification photos

Published April 13th, 2025 by Lisbeth Roy

SOT as Potential Treatment for Viral Infections and Lyme Disease - Nov. 2022

Published April 13th, 2025 by Lisbeth Roy

Abstract: Antisense therapy is widely used as an alternative therapeutic option for various diseases. RNA interference might be effective in infections, through the degradation of messenger RNA and, therefore, translation process. Hence, proteins essential for microorganisms and viruses’ proliferation and metabolism are inhibited, leading to their e

Q-REstrain Therapy

Published April 13th, 2025 by Lisbeth Roy

The Q-REstrain therapy RGCC International offers is an innovative treatment using RNA interference (RNAi) technology. This advanced approach targets cancer cells, viruses, or microorganisms such as Lyme disease with exceptional precision, disrupting their ability to reproduce and survive. Here's an overview of the therapy: How Q-REstrain Works RNA I

Dendritic Cell Therapy - Patient Guide

Published April 10th, 2025 by Lisbeth Roy

What are DENDRITIC CELLS? Dendritic Cells (DCs) are known as antigen presenting cells. They are special key regulators of the Immune system capable of activating the T-Cells and stimulating the growth and differentiation of B-Cells. Dendritic cells identify specific protein markers known as peptides on the surface of foreign or invading cells. DCs t

RGCC- Cell Therapies v2

Published April 11th, 2025 by Lisbeth Roy

RGCC Available Additional Substances

Published April 11th, 2025 by Lisbeth Roy

Vaccine Prep - Comprehensive Guide

Published April 13th, 2025 by Lisbeth Roy

What is Vaccine prep therapy? RGCC’s Vaccine prep therapy uses tumor cell antigens that are produced from the patients’ isolated circulating tumor cells. Tumor cells from each patient potentially carry gene mutations encoding for unique TAAs that are important in stimulatingeffective and long-lasting anti-tumor responses in the patient.  Tumor cells

Vaccine Prep -Comprehensive Guide

Published April 5th, 2025 by Lisbeth Roy

Vaccine prep therapy What is Vaccine prep therapy? RGCC’s Vaccine prep therapy uses tumor cell antigens that are produced from the patients’ isolated circulating tumor cells. Tumor cells from each patient potentially carry gene mutations encoding for unique TAAs that are important in stimulatingeffective and long-lasting anti-tumor responses in the

Substances to Remove

Published April 11th, 2025 by Lisbeth Roy

Substances and Treatments to Remove Intravenous Therapies and Antioxidants Intravenous Vitamin C Ozone Therapy Ultraviolet Blood Irradiation Hydrogen Peroxide (H₂O₂) Therapy Methylene Blue Anti-Inflammatory and Immunomodulatory Substances Low Dose Naltrexone (LDN) Quercetin Resveratrol Colloidal Silver Curcumin Targeted and Specialized Medications R

RGCC - TLMSVAXO-Q-RE

Published April 13th, 2025 by Lisbeth Roy

Beyond CLIA

Published February 17th, 2025 by Lisbeth Roy

Presentation Outline Overview of international QMS standards & guidelines CLSI ISO Comparison of CLSI, ISO and CLIA Questions to consider Questions to Consider What international QMS standards/guidelines apply to clinical laboratories? How do these standards/guidelines differ from CLIA? How are they being used within and outside of the US? What

Substance Dosing Spreadsheet

Published March 30th, 2025 by Lisbeth Roy

Substance Class Dosing AGARICUS BLAZEI MURILL C1 2 CAPS BID (Empty Stomach) ARGENTYN 23 (COLLOIDAL SILVER) C1 15ML TID ARTECIN (FULL SPECTRUM WORMWOOD) C1 2 CAPS BID (No EBOO Days) ARTEMISININ C1 2 CAPS BID (No Weekends, No EBOO Days, Take with Fatty Food) ASCORBIC ACID C1 5GM BID (No Oral Vit C on IV Days) 15ML BLACK CUMIN C1 2 CAPS BID BUTYRIC ACI

RGCC Practitioner Training Guide

Published March 29th, 2025 by Lisbeth Roy

A Comprehensive Guide to RGCC Testing & Therapy Implementation Introduction to RGCC Testing & Therapies RGCC (Research Genetic Cancer Center) offers cutting-edge genetic, immune, and molecular testing for personalized cancer treatment, as well as advanced cellular and gene-based therapies. These tools help practitioners tailor treatments bas

PrecisionPath Treatment Design

Published March 29th, 2025 by Lisbeth Roy

PrecisionPath Treatment Design.xlsx

TUMOR LYSIS MANAGEMENT - 2023

Published April 5th, 2025 by Lisbeth Roy

Important: This is NOT complete and total information on this subject. This is just standard/general information with standard recommendations; it is imperative that you know how to handle TLS and that you do your own due diligence to stay up on the latest information. In tumor lysis syndrome, a constellation of clinical symptoms may develop prior t

Quick Guide for Immune Frame and Vaccine Therapy

Published March 29th, 2025 by Lisbeth Roy

Purpose of the Immune Frame Test Provides a baseline immune status before starting RGCC cellular therapy. Screens for high-risk markers that may impact therapy effectiveness. It helps in monitoring immune response post-therapy every 6 months. Pre-Therapy Testing Requirements Order within 3 months of planned cellular therapy. A CTC test is also requi

SUBSTANCE DOSING FOR RGCC PROTOCOLS

Published March 29th, 2025 by Lisbeth Roy

SUBSTANCE DOSING CLASS 1: AGARICUS BLAZEI MURILL (C1 %) 2 CAPS BID TAKEN ON EMPTY STOMACH ARGENTYN 23 (COLLOIDAL SILVER) (C1 %) 15ML TID ARTECIN (FULL SPECTRUM WORMWOOD) (C1 %) 2 CAPS BID- DO NOT TAKE ON DAYS OF EBOO ARTEMISININ (C1 %) DOSING: 2 CAP BID- TAKE OFF WEEKENDS- TAKE WITH FATTY FOOD |NO ARTEMISININ ON DAY OF EBOO ASCORBIC ACID (C1 %)5GM B

Biomarkers Reference Guide - Providers

Published April 3rd, 2025 by Lisbeth Roy

Growth Factors Proliferation Stimuli (6/19) P180 Ribosome-binding protein 1 or RRBP1 RRBP1 is detected as a ribosome-binding protein located on the rough ER and associated with unfolding protein response. It is upregulated in a wide variety of cancer cells. RRBP1 could alleviate ER stress and help cancer cells survive. Function is pre-protein for ce